Sponsored by AbbVie Medical Affairs
Janet Pope Janetbirdope
3 months 2 weeks ago
Elegant talk of #interferon #gamma in
#pyoderma #gangrenosum
Vs #PG + #pyogenic #arthritis +#acne
#autoinflammatory #syndromes #Papa syn
IL18 differences between PG alone and together in syndrome
#JAKi May be helpful
#EULAR2024 @eular_org @RheumNow @ARD_BMJ @ACR_Journals https://t.co/plYldVdolS
David Liew drdavidliew
3 months 2 weeks ago
In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting.
Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS
then puts up some confronting points. Interesting
#EULAR2024 @RheumNow https://t.co/7zomungi3e
David Liew drdavidliew
3 months 2 weeks ago
I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801223940318351737/photo/1
- https://twitter.com/drdavidliew/status/1801196482995101974
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs
D2T RA pts characterised by
⏰ Earlier disease
⏰ Later initiation of DMARD therapy
Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used
#EULAR2024 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0140-When should we give #pneumococcal #vaccine to pts starting MTX?
Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX
⏩Vaccinate patients before starting MTX!
@RheumNow #EULAR2024
David Liew drdavidliew
3 months 2 weeks ago
When patients say their joints are swollen, what does it mean?
Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows:
- some correlation with MRI/USS findings
- predicts RA development
still worthwhile!
#EULAR2024 POS0609 @RheumNow https://t.co/dw2p5Eo26C
Janet Pope Janetbirdope
3 months 2 weeks ago
#Editors Picks @eular_org @ARD_BMJ @ACR_Journals
Can #rheumatologists effectively #dx of #ankylosing #spondylitis?
👍
552 pts - 1/3 axSpA w high certainty
Certainty of #dx changed over time
2 features
#sacroileitis
good #nSAID response
#EULAR2024 @RheumNow https://t.co/NN3GZTmgn9
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0059 Propensity match scoring of 179 pts w #lupus nephritis in AURA & AURORA1 vs ALMS. Triple therapy (voclosporin + MMF2g/d + low dose GC) led to earlier, greater reduction in proteinuria, & improved safety profile vs dual (MMF3g/d or Cyclo + High dose GC) @RheumNow https://t.co/UdcuaRTtzC
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0017 If one target isn’t enough, why not two! Open label Phase I showed a double-pronged approach, compound BCMA-CD19 CAR Tcells (cCAR) improved clinical response, autoabs elimination & minimal infection in severe refractory #lupus nephritis @RheumNow #EULARBEST https://t.co/6MPHZKxKTB
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793